Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck

Clinical Cancer Research

Volumn 10, Issue 17, 2004, Pages 5930-5939

  Chen, Zhuo ^a   Zhang, Xin ^a   Li, Mengfeng ^b   Wang, Zhiqiang ^b   Wieand, H Samuel ^b   Grandis, Jennifer R ^c   Shin, Dong M ^a,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; PROSTAGLANDIN E2; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG POTENTIATION; FLOW CYTOMETRY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NICK END LABELING; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN TARGETING; SQUAMOUS CELL CARCINOMA;

ANGIOGENESIS INHIBITORS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN SITU NICK-END LABELING; ISOENZYMES; LARYNGEAL NEOPLASMS; LYMPHATIC METASTASIS; MEMBRANE PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SULFONAMIDES; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; TYRPHOSTINS;

EID: 4444324184     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0677     Document Type: Article

References (53)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA - Cancer J Clin 2002;52:23-47.
2. Forastiere AA, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2002;345:1890-1900.
3. Kim ES, Hong WK, Khuri FR. Chemoprevention of aerodigestive tract cancer. Annu Rev Med 2002;53:223-43.
4. Shin DM, Hittelman WN, Hong WK. Biomarkers in upper aerodigestive tract tumorigenesis: a review. Cancer Epidemiol Biomark Prev 1994;3:679-709.
5. Jefferies S, Foulkes WD. Genetic mechanisms in squamous cell carcinoma of the head and neck. Oral Oncol 2001;37:115-26.
6. Shah JP, Strong EW, DeCosse JJ, Ltri L, Sellers P. Effect of retinoids on oral leukoplakia. Am J Surg 1983;146:466-70.
7. Chiesa F, Tradati N, Marazza M, et al. Prevention of local relapse and new localizations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results. Eur J Cancer B Oral Oncol 1992;28B:97-102.
8. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-84.
9. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000;60(Suppl 1):15-23.
10. Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in multistep process of head and neck tumorigenesis. Cancer Res 1994;4:3153-9.
11. Grandis JR, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst (Bethesda) 1998;90:824-32.
12. Boscheli DH. Small molecule inhibitors of receptor tyrosine kinases. Drugs Future 1999;24:515-37.
13. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996;1299:125-40.
14. Subbaramaiah K, Telang N, Ramonetti JT, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996;56:4424-9.
15. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochem Biophys Acta 2000;1470:M69-78.
16. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59:991-4.
17. Peng J-P, Su C-Y, Chang H-C, Chai C-Y, Hung W-C. Overexpression of Cyclooxygenase 2 in squamous cell carcinoma of hypopharynx. Hum Pathol 2002;33:100-4.
18. Marnett LJ, DuBois R. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol 2002;42:55-80.
19. Thun MJ, Henley SJ, Patrono J. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst (Bethesda) 2002;94:252-66.
20. Brenner DE. Multiagent chemopreventive agent combinations. J Cell Biochem Suppl 2000;34:121-4.
21. Papadimitrakopoulou VA, Clayman G, Shin DM, et al. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 1999;125:1083-9.
22. Beckhardt RN, Kiyokawa N, Xi L, et al. HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1995;21:1265-70.
23. Sacks P. Cell, tissue and organ culture as in vitro model to study the biology of squamous cell carcinomas of the head and neck. Cancer Metastasis Rev 1996;15:27-51.
24. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst (Bethesda) 1990;82:1107-12.
25. Maheshwari RK, Srikantan V, Bhartiya D, Kleinman HK, Grant DS. Differential effects of interferon gamma and alpha on in vitro model of angiogenesis. J Cell Physiol 1991;146:164-9.
26. Bunn PA, Frankin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002;29(5 Suppl 14):38-44.
27. 2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-93.
28. Kinoshita K, Takahashi Y, Salashita T, Inoue H, Tanabe T, Yoshimoto T. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochem Biophys Acta 1999;1483:120-30.
29. Matsuura H, Sakaue M, Subbaramaiah K, et al. Regulation of cyclooxygenase-2 by interferon gamma and transforming growth factor alpha in normal human epidermal keratinocytes and squamous carcinoma cells. J Biol Chem 1999;274:29138-48.
30. Torrance CJ, Jackson PE, Montgomery E, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000;6:1024-8.
31. Tortora G, Caputo R, Damiano R, et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase a antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 2003; 9:1566-72.
32. Cohen EEW, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-7.
33. Norman P. ZD-1839 (AstraZeneca). Curr Opin Investig Drugs 2001;2:428-34.
34. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2004;22:77-85.
35. Chiarugi V, Magnelli L, Gallo O. Cox-2, iNOS and p53 as playmakers of tumor angiogenesis. Int J Mol Med 1998;2(6):715-9.
36. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70.
37. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiform pathophysiology. Mol Biol Cell 1993;4:121-33.
38. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000;60:2926-35.
39. Li M, Ye C, Feng C, et al. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clin Cancer Res 2002;8:3570-8.
40. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60:1306-11.
41. 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 2001;7:1041-7.
42. Ashton AW, Yokota R, John G, et al. Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A(2). J Biol Chem 1999;274:35562-70.
43. Waf1/Cip1. Cancer Lett 2003;189:39-48.
44. 2 synthase-2 expression in primary human amnion cells by tyrosine kinase dependent mechanisms. Biochem Biophys Acta 1998;1391:37-51.
45. waf1/cip1-dependent and p-53-independent mechanism. Proc Am Assoc Cancer Res 2004;45:195.
46. Hwang DH, Fung V, Dannenberg AJ. National cancer institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanism. Neoplasia 2002;4:91-7.
47. Grosch S, Tegeder I, Niederberger E, Brautigam L, Gesslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by selective COX-2 inhibitor celecoxib. FASEB J 2001;15: 2742-4.
48. Song X, Lin H-P, Johnson AJ, et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst (Bethesda) 2002;94:585-91.
49. Hawk ET, Viner JL, Dannenberg A, DuBois RN. COX-2 in cancer: a player that's defining the rules. J Natl Cancer Inst (Bethesda) 2002; 94:545-6.
50. Campiglio M, Locatelli A, Olgiati C, et al. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level. J Cell Physiol 2004;198:259-68.
51. Woods KV, El-Naggar A, Clayman GL, Grimm EA. Variable expression of cytokines in human head and neck squamous cell carcinoma cell lines and consistent expression in surgical specimens. Cancer Res 1998;58:3132-41.
52. Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 2003;63:2948-56.
53. Liu X, Kirschenbaum K, Lu M, et al. Prostaglandin E2 stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway, Biochem Biophys Res Comm 2002;290:249-55.